Israel: Researchers from Israel found that empirical therapy with Macrolides like Azithromycin and Roxithromycin has lessened the mortality by 45% in hospitalized bacteremic pneumococcal pneumonia (BPP) without even the necessity for a full course of therapy. The study results were published in the journal Clinical Infectious Diseases.
Community-acquired pneumonia frequently causes hospitalization and death. Empirical therapy guidelines recommend the use of either combination therapy with a β-lactam and an advanced macrolide (azithromycin or clarithromycin) or mono-therapy with respiratory quinolones in hospitalized community-acquired pneumonia patients. As previous literature suggested lower mortality with advanced macrolides, Michal Chowers and the team from Israel conducted a study to characterize antibiotic treatment patterns and assess the role of quinolones or macrolides in empirical therapy.
As a part of an ongoing, nationwide, prospective, population-based, active surveillance of pneumococcal bacteremia adult cases data was collected from all 26 hospitals and 1 major outpatient health maintenance organization from 1 July 2009 to 30 June 2017 in Israel. Cases without information on antibiotic treatment were excluded. A BPP case was defined by the isolation of Streptococcus pneumoniae from blood, with infiltrates on imaging. The independent predictors of in-hospital mortality were assessed by logistic regression analysis.
Key findings:
- A total of 2016 patients with BPP having a median age was 67.2 years were identified. Among them 55.1% were men.
- Lobar pneumonia was present in 1440 (71.4%), and multi-lobar in 576 (28.6%).
- The Median length of hospital stay was 6 days (IQR 4-11).
- empiric antibiotics with anti-pneumococcal coverage like ceftriaxone were given in 1267 (62.8%) out of a total of 1921 cases (95.3%).
- The coverage to atypical bacteria was given in 1159 (57.5%), of which 64% were with macrolides.
- A total of 372 (18.5%) required mechanical ventilation, and 397 (19.7%) died.
- Age, being at high-risk for pneumococcal disease, and multi-lobar pneumonia were the independent predictors of mortality.
- The predictors of survival were the female sex and macrolide therapy.
- Either azithromycin or roxithromycin treatment for as short as two days was a predictor of survival. Quinolone therapy had no effect.
Thus, a short-duration macrolide therapy was protective against in-hospital mortality in this large cohort of patients with BPP.
Further reading: Chowers M, Gerassy-Vainberg S, Cohen-Poradosu R, et al. The Effect of Macrolides on Mortality in Bacteremic Pneumococcal Pneumonia: A Retrospective, Nationwide Cohort Study, Israel, 2009-2017. Clin Infect Dis. 2022;75(12):2219-2224. doi: 10.1093/cid/ciac317
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.